DBV Technologies | DBVT - Current Liabilities

Stock Price
21.14
Daily Change
-0.32 -1.49%
Monthly
-2.45%
Yearly
381.00%
Q1 Forecast
20.91

DBV Technologies reported $49.48M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 182.23M 3.71M Sep/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
DBV Technologies USD 49.48M 60K Sep/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 546.3M 19.2M Sep/2025